Companies › Angitia
1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AGA2115 Unclear mechanism targeting COL1A1 and/or COL1A2 genetic variations in osteogenesis imperf | – | Phase 2 | Osteogenesis Imperfecta (OI) | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07062588 | AGA2115 | Phase 2 | Osteogenesis Imperfecta (OI) | Other | Nov 2027 |
No annotated target.
–
Zynerba Pharmaceuticals Nocion Therapeutics Angitia Biopharmaceuticals Guangzhou Next Life Sciences Aelis Farma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.